PHILADELPHIA — Giving the SGLT-2 inhibitor dapagliflozin (Farxiga) to patients with acute myocardial infarction (MI) and impaired left ventricular systolic ...
A small, nonmechanical, implanted device that continuously releases the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) and designed for ...
Once-daily treatment with the selective aldosterone synthase inhibitor lorundrostat (Mineralys Therapeutics) safely and significantly reduced blood pressure in adults with ...
People with chronic kidney disease (CKD) and an episode of mild or moderate acute kidney injury (AKI) subsequently have a ...
Dapagliflozin (Farxiga) appears to be no more effective than the "thiazide-like" diuretic metolazone at improving pulmonary congestion and fluid status ...
More than three quarters of patients with chronic limb-threatening ischemia (CLTI) and no revascularization options were able to avoid above-the-ankle ...
The Society for Cardiovascular Angiography and Interventions has issued an updated expert consensus statement to provide clearer guidance on what ...
WASHINGTON — Adding granulocyte-colony stimulating factor (G-CSF) to steroid therapy can improve 90-day survival for patients with severe alcoholic hepatitis ...
© Pharma News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.